Filtered By:
Management: Government
Vaccination: Cervical Cancer Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 26 results found since Jan 2013.
Prevention and control of HPV and HPV-related cancers in France: the evolving landscape and the way forward - a meeting report
This report covers some critical findings, key challenges, and future steps to improve the status of HPV prevention and control measures in the country.PMID:37537651 | DOI:10.1186/s12919-023-00271-0
Source: Cancer Control - August 3, 2023 Category: Cancer & Oncology Authors: Dur-E-Nayab Waheed Catherine Weil Olivier Didier Riethmuller Eduardo L Franco Jean Luc Pr étet Marc Baay Nubia Munoz Alex Vorsters Source Type: research
Frequency of health care provider recommendations for HPV vaccination: a survey in three large cities in China
DISCUSSION: The frequency of HCPs' recommendations for HPV vaccination in China was much lower than that in many developed countries. To enhance the recommendation frequency, medical institutions should help HCPs gain more knowledge of HPV and master communication skills. At the same time, the government should take measures to enhance the accessibility of HPV vaccines. The media should help to alleviate people's concerns and encourage them to face up sexual health.PMID:37497028 | PMC:PMC10366465 | DOI:10.3389/fpubh.2023.1203610
Source: Cancer Control - July 27, 2023 Category: Cancer & Oncology Authors: Yimeng Mao Yuchen Zhao Lingyun Zhang Jie Li Abu S Abdullah Pinpin Zheng Fan Wang Source Type: research
Managing the transition in cervical screening methods for Taiwan: Policy recommendations and perspectives
J Formos Med Assoc. 2023 Jul 12:S0929-6646(23)00246-2. doi: 10.1016/j.jfma.2023.06.018. Online ahead of print.ABSTRACTSince government-provided annual cervical cytology testing for all Taiwanese women aged 30 years or older became available in 1995, both cervical cancer incidence and death have decreased significantly. However, with the 2018 introduction of the national immunization program for human papillomavirus (HPV) vaccination in all schoolgirls aged 13-15 years old, the positive predictive value of cytology testing is expected to decrease with rising vaccination rates, and therefore a transition to more sensitive HP...
Source: J Formos Med Assoc - July 14, 2023 Category: General Medicine Authors: Chien-Chin Chen Chyong-Huey Lai Chih-Long Chang Wen-Fang Cheng Raoh-Fang Pwu Jane Tsai Peng-Hui Wang Jacqueline Whang-Peng Gi-Ming Lai Source Type: research
Nationwide introduction of HPV vaccine in Zimbabwe 2018-2019: Experiences with multiple cohort vaccination delivery
PLOS Glob Public Health. 2022 Apr 6;2(4):e0000101. doi: 10.1371/journal.pgph.0000101. eCollection 2022.ABSTRACTThe World Health Organization (WHO) recommends the human papillomavirus (HPV) vaccine for girls aged 9-14 years for cervical cancer prevention and encourages vaccinating multiple cohorts in the first year to maximize impact. The HPV vaccine was introduced nationwide in Zimbabwe in 2018 through a 1-week school-based campaign to multiple cohorts (all girls 10-14 years old), followed by a single cohort (grade 5 girls in school and age 10 girls out-of-school) in 2019. During the 2019 campaign, the multiple cohort's se...
Source: Cancer Control - March 24, 2023 Category: Cancer & Oncology Authors: Julie Garon Carlton Joan Marembo Portia Manangazira Maxwell Rupfutse Adelaide Shearley Egnes Makwabarara Anna Hidle Anagha Loharikar Source Type: research
The cost-effectiveness of human papillomavirus vaccination in the Philippines
Vaccine. 2022 May 20:S0264-410X(22)00609-0. doi: 10.1016/j.vaccine.2022.05.025. Online ahead of print.ABSTRACTCervical cancer is the second most common cancer among women in the Philippines. Human papillomavirus (HPV) vaccination provides protection from the most common cancer-causing HPV types. This analysis used a proportionate outcomes model to estimate the potential cost-effectiveness of four different HPV vaccine products-Cervarix™, Cecolin®, GARDASIL®, and GARDASIL®9-for routine HPV vaccination of 10 cohorts of 9-year-old girls from the government and societal perspectives. Model parameters included cervical can...
Source: Vaccine - May 23, 2022 Category: Allergy & Immunology Authors: Cecilia L Llave Maria Esterlita V Uy Hilton Y Lam Josephine G Aldaba Clarence C Yacapin Michelle B Miranda Haidee A Valverde Wilda T Silva Saira Nawaz Rose C Slavkovsky Jessica Mooney Elisabeth L Vodicka Source Type: research
Parents' attitudes, beliefs and uptake of the school-based human papillomavirus (HPV) vaccination program in Jakarta, Indonesia - A quantitative study
We examined parents' beliefs, attitudes and intentions to allow their daughters to receive the HPV vaccine, as well as the uptake of the vaccine. This cross-sectional study was conducted between September and November 2019 in Jakarta. We invited 680 parents or guardians of year 6 female students from 33 primary schools who were offered the free HPV vaccine to complete a questionnaire; 484 (71%) responded. Analysis was done in two groups: the 'Decided' Group (those parents who allowed or denied for their daughter to receive the HPV vaccination), and the 'Undecided' Group (those parents who did not recall being approached ab...
Source: Cancer Control - January 3, 2022 Category: Cancer & Oncology Authors: Kurnia Eka Wijayanti Heike Sch ütze Catherine MacPhail Source Type: research
Promoting adolescent health through integrated human papillomavirus vaccination programs: The experience of Togo
Vaccine. 2021 Nov 26:S0264-410X(21)01466-3. doi: 10.1016/j.vaccine.2021.11.021. Online ahead of print.ABSTRACTThe introduction of the Human papillomavirus (HPV) vaccine has shown potential to not only prevent cervical cancer but also drive adolescents' access to other health care services, even in low-income countries. Few studies have been conducted to date to identify best practices and estimate the acceptance, operational challenges and benefits of including broader adolescent health interventions into immunization efforts, knowledge which is essential to supporting widespread integration. In this paper we review the ef...
Source: Vaccine - November 30, 2021 Category: Allergy & Immunology Authors: Danielle Engel Abra Dela Jeanne Afeli Christopher Morgan Willibald Zeck David A Ross Joseph Vyankandondera Paul Bloem Kodjovi Robert Adjeoda Source Type: research
National introduction of HPV vaccination in Senegal-Successes, challenges, and lessons learned
Vaccine. 2021 Sep 27:S0264-410X(21)01075-6. doi: 10.1016/j.vaccine.2021.08.042. Online ahead of print.ABSTRACTFollowing successful school-based demonstration programs in 2014-2016, the human papillomavirus (HPV) vaccine was introduced nationwide in Senegal for 9-year-old girls in 2018, using a routine service delivery strategy at health facilities, schools, and other outreach sites. We reviewed the HPV vaccine introduction in Senegal to understand the successes, challenges, and lessons learned. Focusing on three key domains (program decision-making, planning, and implementation), we conducted ten semi-structured interviews...
Source: Vaccine - October 1, 2021 Category: Allergy & Immunology Authors: Rebecca M Casey Nedghie Adrien Ousseynou Badiane Aliou Diallo Jerlie Loko Roka Timothy Brennan Reena Doshi Julie Garon Anagha Loharikar Source Type: research
Access to HPV vaccination in Japan: Increasing social trust to regain vaccine confidence
Vaccine. 2021 Sep 7:S0264-410X(21)01145-2. doi: 10.1016/j.vaccine.2021.08.085. Online ahead of print.ABSTRACTVaccine hesitancy is a growing concern in global public health, and illustrates serious problems arising from loss of social trust. Japan is experiencing a human papillomavirus (HPV) vaccine crisis that started with a rapid decline in the vaccination rate in 2013 from approximately 70% to less than 1% and lasting for 7 years. We analyze Japan's case of vaccine hesitancy for HPV vaccine, using a framework for examining barriers to access and use of health technologies according to four categories: architecture, avail...
Source: Vaccine - September 11, 2021 Category: Allergy & Immunology Authors: Keiko Kunitoki Masafumi Funato Makiko Mitsunami Takahiro Kinoshita Michael R Reich Source Type: research
